For cognitive and depression outcomes, two meta-analyses based on both interventional and observational data had shown a promising effect of GLP1-RAs, but the number of studies and participants was low, data for the recently-approved semaglutide was scant, and heterogeneity was high. This evidence concerns the gene GLP1R and depressive disorder.